Key Points
- CEO Ying Du sold 2,653 shares on April 6 at an average price of $20.45 to cover tax withholding on vested equity, leaving her with 1,122,626 shares (a 0.24% reduction) valued at about $22.96M.
- Zai Lab reported quarterly EPS of ($0.50) on $127.6M in revenue, with a negative net margin (38.15%) and negative ROE, and the company has a market cap of roughly $2.41B and a 52‑week range of $15.96–$44.34.
- Analyst views are mixed but MarketBeat shows a consensus "Moderate Buy" with a $50.00 target, while institutional investors own about 41.65% of the stock.
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 853 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $20.45, for a total value of $17,443.85. Following the sale, the chief financial officer owned 31,705 shares of the company's stock, valued at approximately $648,367.25. This represents a 2.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Yajing Chen also recently made the following trade(s):
- On Thursday, April 2nd, Yajing Chen sold 5,199 shares of Zai Lab stock. The stock was sold at an average price of $20.39, for a total value of $106,007.61.
- On Friday, March 13th, Yajing Chen sold 1,703 shares of Zai Lab stock. The stock was sold at an average price of $18.63, for a total value of $31,726.89.
Zai Lab Stock Up 1.9%
Zai Lab stock opened at $21.39 on Thursday. The business has a fifty day moving average of $18.89 and a two-hundred day moving average of $21.51. The firm has a market cap of $2.41 billion, a P/E ratio of -13.29 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a twelve month low of $15.96 and a twelve month high of $44.34.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. The company had revenue of $127.60 million for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. Equities analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.
Analysts Set New Price Targets
A number of analysts have weighed in on ZLAB shares. JPMorgan Chase & Co. lowered their target price on Zai Lab from $39.00 to $32.00 and set an "overweight" rating for the company in a report on Wednesday, March 18th. Cantor Fitzgerald lowered their target price on Zai Lab from $55.00 to $37.00 and set an "overweight" rating for the company in a report on Friday, February 27th. Weiss Ratings restated a "sell (d-)" rating on shares of Zai Lab in a report on Wednesday, January 21st. Jefferies Financial Group upgraded Zai Lab to a "strong-buy" rating in a report on Monday, January 19th. Finally, UBS Group initiated coverage on Zai Lab in a report on Wednesday, January 7th. They set a "buy" rating and a $35.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $50.00.
View Our Latest Research Report on Zai Lab
Institutional Investors Weigh In On Zai Lab
An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 6.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 10,396 shares of the company's stock after purchasing an additional 642 shares during the period. SG Americas Securities LLC's holdings in Zai Lab were worth $183,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 41.65% of the company's stock.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
